Garry M. Walsh

Dr. Garry M. Walsh

Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, UK

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 1998 in Journal of Immunological Methods
Verified
Journal Article
Closed access
Garry M. WalshGarry M. Walsh
Garry M. Walsh
GDGrant Dewson
Grant Dewson
AWAndrew J Wardlaw
Andrew J Wardlaw
FLFrancesca Levi-Schaffer
Francesca Levi-Schaffer
RMRedwan Moqbel
Redwan Moqbel

1 January 2001 in Current Opinion in Hematology
Verified
Journal Article
Closed access
Garry M. WalshGarry M. Walsh
Garry M. Walsh
The eosinophil has a potent armory of proinflammatory mediators with considerable potential to initiate and sustain an inflammatory response. These include cytotoxic granule proteins, cytokines, chemokines, and lipid mediators. Eosinophils are considered important in the immune response to infection with helminthic parasitic worms. Incrementally increasing evidence supports a critical role for their proinflammatory activities in diverse human conditions, most notably in allergic diseases such as asthma. In these conditions severe tissue damage is a consequence of an inappropriate accumulation of eosinophils and the subsequent release of their highly toxic granule proteins. In addition, release of granule-associated products such as chemokines and cytokines at the sites of inflammation is likely to have significant paracrine and autocrine relevance. This review will update recent developments in understanding the role that eosinophil granule proteins play in human disease, particularly those of the respiratory tract.

1 January 2001 in Drugs
Verified
Journal Article
Closed access
PDF file
Garry M. WalshGarry M. Walsh
Garry M. Walsh
LALUCIO ANNUNZIATO
LUCIO ANNUNZIATO
NFNelly Frossard
Nelly Frossard
KKKlaas Knol
Klaas Knol
SLSten Levander
Sten Levander
HTHenk Timmerman
Henk Timmerman

15 October 1999 in Blood
Verified
Journal Article
Open access
Garry M. WalshGarry M. Walsh
Garry M. Walsh
DSDarren Sexton
Darren Sexton
MBMorgan G. Blaylock
Morgan G. Blaylock
CCCatherine M. Convery
Catherine M. Convery
Eosinophils, which are prominent cells in asthmatic inflammation, undergo apoptosis and are recognized and engulfed by phagocytic macrophages in vitro. We have examined the ability of human small airway epithelial cells (SAEC) to recognize and ingest apoptotic human eosinophils. Cultured SAEC ingested apoptotic eosinophils but not freshly isolated eosinophils or opsonized erythrocytes. The ability of SAEC to ingest apoptotic eosinophils was enhanced by interleukin-1 (IL-1) or tumor necrosis factor  (TNF) in a time- and concentration-dependent fashion. IL-1 was found to be more potent than TNF and each was optimal at 10−10 mol/L, with a significant (P < .05) effect observed at 1 hour postcytokine incubation that was maximal at 5 hours. IL-1 stimulation not only increased the number of SAEC engulfing apoptotic eosinophils, but also enhanced their capacity for ingestion. The amino sugars glucosamine, n-acetyl glucosamine, and galactosamine significantly inhibited uptake of apoptotic eosinophils by both resting and IL-1–stimulated SAEC, in contrast to the parent sugars glucose, galactose, mannose, and fucose. Incubation of apoptotic eosinophils with the tetrapeptide RGDS, but not RGES, significantly inhibited their uptake by both resting and IL-1–stimulated SAEC, as did monoclonal antibody against vβ3 and CD36. Thus, SAEC recognize apoptotic eosinophils via lectin- and integrin-dependent mechanisms. These data demonstrate a novel function for human bronchial epithelial cells that might represent an important mechanism in the resolution of eosinophil-induced asthmatic inflammation.

19 August 2002 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
PDF file
LTL. Thomson
L. Thomson
MBM. G. Blaylock
M. G. Blaylock
DSDarren Sexton
Darren Sexton
ACA. Campbell
A. Campbell
Garry M. WalshGarry M. Walsh
Garry M. Walsh

1 January 2013 in Journal of Cell Death
Verified
Journal Article
Open access
PDF file
Garry M. WalshGarry M. Walsh
Garry M. Walsh
Asthma is an increasingly common respiratory condition characterized by reversible airway obstruction, bronchial hyper-responsiveness and airway inflammation with a clear unmet need for more effective therapy. Eosinophilic asthma is a phenotype of the condition that features increased blood or sputum eosinophils whose numbers correlate with disease severity. Several lines of evidence are now emerging, which implicate increased persistence of eosinophils in the lungs of patients with asthma as a consequence of inhibition of and defects in the apoptotic process, together with impaired apoptotic cell removal mechanisms. This article will update our knowledge of the mechanisms controlling eosinophil apoptosis and clearance, together with evidence implicating defects in apoptosis and pro-inflammatory cell removal in asthma. Recent developments in novel therapies for asthma that target eosinophil apoptotic and/or clearance pathways will also be discussed.